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Rationale and Objectives: Development of imaging biomarkers often relies on their correlation with histopathology. Our aim was to
compare two approaches for correlating pathology to multiparametric magnetic resonance (MR) imaging (mpMRI) for localization and
quantitative assessment of prostate cancer (PCa) index tumor using whole mount (WM) pathology (WMP) as the reference.
Materials and Methods: Patients (N = 30) underwent mpMRI that included diffusion-weighted imaging and dynamic contrast-enhanced
(DCE) MRI at 3 T before radical prostatectomy (RP). RP specimens were processed usingWM technique (WMP) and findings summarized
in a standard surgical pathology report (SPR). Histology index tumor volumes (HTVs) were compared toMR tumor volumes (MRTVs) using
two approaches for index lesion identification onmpMRI using annotatedWMPslides as the reference (WMP) and using routine SPR as the
reference. Consistency of index tumor localization, tumor volume, andmean values of the derived quantitative parameters (mean apparent
diffusion coefficient [ADC], Ktrans, and ve) were compared.
Results: Index lesions from16 of 30 patientsmet the selection criteria. TherewasWMP/SRP agreement in index tumor in 13 of 16 patients.
ADC-based MRTVs were larger (P < .05) than DCE-basedMRTVs. ADCMRTVs were smaller than HTV (P < .005). There was a strong cor-
relation between HTV andMRTV (Pearson r > 0.8; P < .05). No significant differences were observed in the mean values of Ktrans and ADC
between the WMP and SPR.
Conclusions: WMP correlation is superior to SPR for accurate localization of all index lesions. The use of WMP is however not required to
distinguish significant differences of mean values of quantitative MRI parameters within tumor volume.
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agnetic resonance (MR) imaging (MRI) of the
prostate has become an essential modality for stag-
ing and characterizing prostate cancer (PCa)
(1,2). Current imaging protocols use multiparametric MRI
(mpMRI) with diffusion-weighted imaging (DWI) andAcad Radiol 2015; 22:548–555
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548dynamic contrast-enhanced (DCE) MRI in addition to
conventional T2- and T1-weighted imaging for a comprehen-
sive assessment of PCa. The current recommendations for the
clinical use ofMRI rely on the qualitative assessment of theMR
parameters (2,3), but much work is currently being done to
refine mpMRI acquisitions, analyses, and validations to
establish the clinical utility of quantitative prostate imaging.
Each individual imaging sequence can provide unique and
complementary quantitative measurements of the underlying
physiology and pathophysiology of the prostate tissue, leading
to improved detection of PCa (4,5). However, exactly what
pathophysiology these quantitative measurements represent is
not well established.
Development and validation of quantitative imaging tools re-
quires correlation with established markers of the disease. A
pathology-derived Gleason score remains the cornerstone for
decision making with regard to therapy selection and disease
prognosis (6). As such, numerous studies have been conducted
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the purposes of localizing the lesion and assessing its aggressive-
ness (7,8). Likewise, correlationwith histology is also a necessary
component in the validation of mpMRI as a means of response
to therapy. However, the methods used for pathologic
correlation vary widely, ranging from in-depth whole mount
(WM) processing of the specimen followed by delineation of
tumor foci by a pathologist directly on the glass sides and com-
parison to MRI data, to simply correlating MR images to the
standard clinical pathology report. These two correlative pathol-
ogyapproaches are very different in termsof resources, expertise,
and time involvement. WM pathology (WMP) correlation re-
quires a technologist with expertise inWMfixation, embedding
and sectioning, extensive pathologist involvement and is consid-
ered the ‘‘gold standard’’ for an imaging correlative approach. In
contrast to standard pathologic processing used routinely, where
individual cross-sections of the prostate are further cut into four
quadrants or more, WMP allows for increased accuracy of the
spatialmappingbetweenpathology specimen and images, as axial
sections of the prostate specimen are processed using large WM
slides, which are marked to facilitate volumetric reconstruction
of the specimen. The tumor areas are next contoured on each
slide, thus simplifying spatial localization of the matching lesions
in the imaging data. This in-depth correlative approach has been
used by many (8–10). In contrast, a more common routine
processing protocol provides pathology information necessary
for clinical decision making, and including overall Gleason
score and whether or not there is an extracapsular extension of
tumor, it may include one- or two-dimensional measurement
of the tumor area(s). As such, routine processing does not allow
for volumetric reconstruction of the specimen, and so, three-
dimensional volumescannot beeasilyestimated.The surgical pa-
thology report (SPR) is therefore not focused on providing
detailed information for validating imaging studies. However,
given the ubiquitous availability of SPR data, and the relatively
low cost of implementing imaging correlative studies that rely
on SPR, the practical question iswhether SPR alone is sufficient
for accurate localization of PCa. If the index lesion is correctly
localized, it is unknown whether the assumed improvement in
the accuracy of tumor delineation using WMP leads to signifi-
cant differences in the tumor volume outlined, or differences
in the quantitative MR parameters obtained.
In this study, we compare two types of pathology to MR
correlation approaches, WMP and SPR, for prostate tumor
localization and delineation.Our goal is to investigatewhether
the choice of the correlation approach has an effect on index
tumor detection and localization, andwhether outlined tumor
volume and quantitativempMRImetrics in areas of tumor and
noncancerous tissue differ between pathologic approaches.MATERIALS AND METHODS
Patients
Thirtymale patients (median age, 63 years; range, 45–69 years)
with biopsy-confirmed PCa were consented to participate inthe research study. Inclusion criteria were ability of the patient
to undergo endorectal coil prostate MR, radical prostatec-
tomy as a treatment plan, and an elevated serum prostate-
specific antigen (PSA) level within 6 weeks before imaging.
MR Imaging
All MRI examinations were performed on a GE Signa HDx
3.0 T magnet (GE Healthcare, Waukesha, WI) using a combi-
nation of eight-channel abdominal array and endorectal coil
(Medrad, Pittsburgh, PA). The mpMRI protocol (1) included
T1-weighted imaging (spoiled gradient recalled acquisition in
steady state [SPGR] sequence, repetition time [TR]/echo
time [TE]/a = 385 ms/6.2 ms/65, over a 16-cm2 field of
view [FOV]), T2-weighted imaging (fast relaxation fast spin
echo [FRFSE] sequence, TR/TE = 3500 ms/102 ms over a
16-cm2 FOV), and DWI (single-shot echo planar imaging
[EPI] sequence, TR/TE = 2500 ms/65 ms with b-values of
0 and 500 s/mm2). DCE MRI was performed with a 3D
SPGR sequence, TR/TE/a = 3.6 ms/1.3 ms/15, FOV
26 cm, with full-gland coverage and reconstructed voxel size
of 1  1  6 mm as interpolated to 256  256 matrices, and
with a temporal resolution of approximately 5 seconds. Gado-
pentetate dimeglumine (Magnevist; Berlex Laboratories,
Wayne, NJ) was injected intravenously using a syringe pump
(0.15 mmol/kg; rate 3 mL/s). The protocol included5 base-
line scans before contrast injection for estimation of baseline
signal intensities.
We note that for a prostate T1 around 1.5 seconds, the Ernst
angle of 35 gives maximum signal for our TR value of 0.385
seconds. As we have noted in (11), however, flip angle (FA)
values particularly at 3 Tare at best ‘‘nominal’’ and canvary quite
a bit over the FOV due to B1 inhomogeneities; so, we work
with an FA of 65 as it is in a relatively flatter region of the signal
versus FA curve making it less sensitive to FAvariation from B1
inhomogeneities than the 35 choice. This larger FA also pro-
vides a heavier T1 weighting to get more sensitivity to the
short-T1 hyperintensities from blood products (eg, biopsy-
related hemorrhage); so, we prefer this to optimizing prostate
tissue signal as this is one of the major reasons for this initial
SPGR sequence.
Image Processing
DWI apparent diffusion coefficient (ADC) maps derived from
b500 DWI and subtraction DCE images (calculated as the dif-
ference between the phase corresponding to the contrast bolus
arrival and the baseline phase) were generated by the scanner
software. Generalized kinetic model (12) was applied to the
DCE MRI data to derive pharmacokinetic (PK) maps of for-
ward volume transfer constant (Ktrans, minute1) and the frac-
tional volume of extracellular space per unit volume of tissue
(ne). PK analysis was done using OncoQuant research proto-
type software (GE Global Research, Niskayuna, NY). The
two-parameter model without a plasma volume fraction
term was chosen because of the temporal resolution of the
prostate DCE MRI data (5 seconds). The initial precontrast549
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1600 ms for blood (14) and used to convert signal intensity
to gadolinium concentration (11). For arterial input function
(AIF) initialization, we used a previously computed, fixed,
AIF curve, numerically constructed from published first-
pass data (15) and concatenated with the Weinmann curve
for late wash out (16). This methodology has been previously
reported (17) and was chosen because our imaging and injec-
tion protocol closely match those used in that study. Quality of
the model fits was assessed using the coefficient of determina-
tion (R2). Voxels showing poor fit of the model to the data
(R2 < 0.75) were excluded from the analysis.Histopathology Acquisition and Analysis
Radical prostatectomy specimens were inked for laterality and
fixed in 40% buffered formalin overnight at room tempera-
ture. The first 26 consecutive patients were sectioned manu-
ally from apex to the base, perpendicular to the urethra at
4–5 mm intervals. In the last four patients, a customized indi-
vidual 3Dmolds were used to process the specimens (18). The
molds were fabricated by 3D printing to maintain cutting at
the angle consistent with the slice orientation in the DCE
MRI, and with the section thickness of 3 mm. In all cases,
each slice was annotated by slice number, fixed, and paraffin
embedded. Care was taken in each case to maintain orienta-
tions of each slice of the prostate so that the same sides of
each slice was routinely cut (ie, the superior or inferior edge
for each prostate cross-section), thus allowing for relatively
equal spaces between hematoxylin and eosin (H&E) sections.
Subsequently, 5-m WM tissue sections were cut from each
slice, glass-mounted, and stained with H&E.
All PCa foci in each patient were outlined with a marker on
the glass slide and assigned a Gleason score by the dedicated
genitourinary (GU) pathologist. The annotated WM slides
were digitized using a flatbed scanner (2400 dpi, transparency
unit). Tumor region of interests (ROIs) were manually recon-
toured on the digitizedWM slides using 3D Slicer open source
software (19). Histopathology tumor volumes (HTVs) were
automatically calculated based onmanual contours by assuming
5 mm thickness for routinemanual processing and 3mm thick-
ness for those processed using the customized mold. Volumes
were then scaled by a factor of 1.15 to account for tissue
shrinkage as recommended by Jonmarker et al. (20).Lesion Localization
Correlation analysis was restricted to clinically significant pe-
ripheral zone (PZ) tumors, defined as tumors with HTV >0.5
cc (21,22). For patients with multiple tumors that had HTV$
0.5 cm3, an index lesion was chosen to correlate with
mpMRI. This index lesion was defined as the largest lesion
with the highest assigned Gleason score within each case.
Correlation with mpMRI imaging was performed by a
radiologist with >10 years of experience in prostate MRI
(F.F.). Tumor ROIs corresponding to the index lesion and550ROIs corresponding to noncancerous PZ tissue were
identified using two correlative approaches:
1) Approach 1: WMP pathology-based analysis: digitized
whole mount slides of the radical prostatectomy specimen
containing areas of tumor outlined by a GU pathologist
with >10 years of experience (M.S.H.) were viewed
side by side with mpMRI images (T1-weighted images
[T1W], T2-weighted images [T2W], ADC maps, and
DCE subtraction images) using 3D Slicer. An ROI corre-
sponding to the index lesion (tumor ROI [TROI]), and
an ROI corresponding to a nearby area of nontumor con-
taining tissue (if possible on the same axial slice) were
identified and contoured on mpMRI using anatomic
landmarks such as urethra, verumontanum, prostatic calci-
fications, or benign prostatic hyperplastic nodules.
2) Approach 2: SPR-based analysis: using the clinical stan-
dard of care pathology report, but without access to
WMP images, an index lesion was identified and con-
toured on mpMRI images (T1W, T2W, ADC maps,
and subtract images) using 3D Slicer. An area of nontumor
containing tissue was also delineated, based on mpMRI
maps, on the same or adjacent axial image.
ROIs were identified using WMP approach first, followed
by the SPR approach after 6 months time interval. For each
approach, an index lesion had to demonstrate restricted diffu-
sion on ADC maps, focal low signal intensity on T2W images
(T2WI), and enhancement onDCE subtraction images. Lesion
localizationwas performed based on qualitative assessment of all
mpMRI sequences rather than using specific quantitative cut-
offs for ADC or for DCE. We did not use any fixed thresholds
for lesion identification. Whenever possible, normal ROI was
contoured on the same slice as tumor or in the closest adjacent
slice. All index lesions identified in this manner were contoured
on T2WI, ADC maps, and subtraction DCE images using 3D
Slicer. Zonal anatomic location of each index lesion was
recorded using a 2  3 table (right and left across the base,
the midgland, and the apex). If the tumor occupied multiple
zonal locations, all zones spanned by the tumor were marked.Comparison Analysis
We first evaluated lesions that were localized consistently by
the WMP and SPR approaches based on their coded zonal
anatomic location. Partial agreement in location was inter-
preted as consistent localization (ie, a tumor coded as
Right-Apex in WMP and Right-Apex/Right-Mid in SPR
was considered overlapping). For tumors localized consis-
tently, we proceeded with analysis of volumetric agreement
of the ROIs, ROI spatial overlap, and compared the quantita-
tive mpMRI values extracted from the ROIs.
The paired t test was used for the following reasons:
1) to determine if there was a difference in MR tumor vol-
ume (MRTV) estimates contoured on each mpMRI map
(T2, DCE, and ADC) with two different correlative
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using WMP (MRTVWMP), compared to HTV.
2) to determine if there was a difference in volume between
the TROIs on individual mpMRI parameter maps for
each pathology correlative approach.
3) to compare the quantitative values of MR parameters ex-
tracted from TROIs using the two correlative approaches.
Bonferroni correction was used to adjust for multiple com-
parisons when comparing more than two groups. Bland–Alt-
man analysis was applied to evaluate agreement between the
tumor volumes identified by the two correlation approaches
for the same image, for comparing tumor volumes estimated
using MRI and pathology-estimated volumes and between
each of the mpMRI parameter/map, and the tumor localiza-
tion approach combinations. The relationship between the
HTVs and both MRTVs was also analyzed using the Pearson
correlation coefficient.
Spatial overlap between the WMP- and SPR-based tumor
ROIs was assessed using Dice similarity coefficient (DSC).
The value of DSC is between 0 and 1, the latter corresponding
to perfect overlap.DSC is a commonly usedmeasure commonly
used to assess the agreement between segmented contours (23).
This Health Insurance Portability and Accountability Act
(HIPAA)-compliant prospective study was approved by our
institutional review board.Written informed consent was ob-
tained from all subjects.RESULTS
Study Population
For the initial cohort of 30 patients, the median serum PSA
level was 5.19 ng/dL (range, 2.20–25.95 ng/dL). The mean
number of days between a positive prostate biopsy result and
prostate MR was 73 days (median, 42 days; range, 1–687),
and the mean interval between prostate MR and prostatec-
tomy was 58 days (median, 47 days; range, 10–217 days). A to-
tal of 85 tumor ROIs were identified and contoured on WM
slides. Of these, 44 had a Gleason grade$7, 35 had a Gleason
grade 6, and in six lesions (from three patients); no Gleason
grade was reported owing to prior neoadjuvant chemo-
therapy. A total of 14 patients were excluded from the analysis
because they had TROIs below the 0.5 cc tumor volume
threshold (n = 8), TROI in central gland only (n = 3), had
extensive hemorrhage on MRI limiting visualization of the
tumor (n = 2), or had insufficient image quality (n = 1).
The Gleason score for all 16 TROIs was$7, except for one
patient who had prior therapy and an unassigned Gleason
score. The mean age of these 16 patients was 59 (standard de-
viation [SD] 7; range, 45–69), mean PSA 5.6 (SD, 2.7; range,
2.2–13.6), mean tumor volume in cubic centimeters as
measured on WMP and corrected for fixation shrinkage
1.99 (SD, 1.59; range, 0.56–7.00), mean number of days
from biopsy to MRI 33 (SD, 16; range, 5–59), mean number
of days from MRI to surgery 52 (SD, 51; range, 10–217).Comparative Analysis between Pathologic Approaches
Index Lesion Localization. For all 16 cases, index lesions were
identified and contoured in T2WI, ADC, and subtraction
DCE using both the SPR and the WMP approach. The
anatomic locations of the tumors identified based on SPR
agreed with those outlined based on WMP in 13 of 16 cases.
Figure 1 shows one of the cases where tumor was localized
incorrectly using the SPR localization approach. Only TROIs
that were localized consistently between the SPR and WMP
approaches were included in the subsequent analysis.
Spatial overlap based on Dice similarity coefficient between
the matching tumor ROIs defined using the WMP- and
SPR-based approaches was approximately 0.6 for all MRI
maps (mean  SD): T2, 0.62  0.22; DCE, 0.63  0.13;
ADC500, 0.60  0.17.
Tumor Volume Assessment. Mean (SD) HTV measurements
were 1992 (1655) mm3. MR-based TROI volume measure-
ments for the individual maps are summarized in Table 1.
For both correlative approaches, MRTVs were on average
largest when contoured on DCE and smallest on ADC.
Bland–Altman plots for individual combinations of parame-
ters are shown in Figure 2. MRTVs estimated using both
WMP and SPR approaches had a moderate-to-high correla-
tion with HTV for T2WI, ADC, and DCE subtraction maps
(WMP: T2WI, 0.67; DCE, 0.82; ADC500, 0.96; SPR:
T2WI, 0.95; DCE, 0.82; ADC, 0.96; all P < .05).
Based on pairwise comparisons between the means of
HTV, MRTVWMP, and MRTVSPR, we observed a significant
difference between the MRTVSPR approach and HTV for
volumes outlined based on T2 (P = .0024) and ADC500
(P = .0004). The mean difference between tumor volumes
estimated from ADC and DCE maps was 780 mm3
(P < .0005) when WMP approach was used, and 524 mm3
(P < .02) for the SPR approach.Comparison of Quantitative Multiparametric
Parameters between Tumor and Nontumor ROIs
PK analysis resulted in good fits of the model to the data in the
majority of voxels. On average, <5% of voxels were discarded
based on the R2 quality of fit measure. Means of the parameter
values measured over tumor ROIs are summarized in Table 2.
Differences between the means of the quantitative parameter
values measured over tumorROIs defined with theWMPand
SPR approaches were not statistically significant. Mean ROI
values of the quantitative parameters (Ktrans, ve, and ADC)
were significantly different between the tumor and normal
areas both for WMP and SPR approaches (P < .05).DISCUSSION
Correlation of imaging with histology is critical for validation
and for establishing the utility of novel imaging biomarkers.
More specifically, accurate correlation enables analyses of551
TABLE 1. Tumor VolumeEstimates From the IndividualMRI SequencesUsing SPRandWMPCorrelative Approaches (MRTVSPR and
MRTVWMP, Respectively) and Their Differences Versus HTV
mpMRI Parameter Mean (SD) MRTVSPR, mm
3
Mean (SD) Difference
between HTV and
MRTVSPR, mm
3
Mean (SD)
MRTVWMP, mm
3
Mean (SD) Difference
between HTV and
MRTVWMP, mm
3
T2WI 1073 (1022)* 919 (745) 1376 (1176) 626 (1229)
DCE 1314 (974) 678 (1021) 1711 (1303) 280 (940)
ADC 790 (950)* 1202 (794) 931 (1036)* 1061 (730)
ADC, apparent diffusion coefficient; DCE, dynamic contrast enhanced; HTV, histology index tumor volume;mpMRI,multiparametric magnetic
resonance imaging; MRI, magnetic resonance imaging; MRTV, magnetic resonance tumor volumes; SD, standard deviation; SPR, surgical pa-
thology report; T2WI, T2-weighted imaging; WMP, whole mount pathology.
MRI-based measurements that were significantly smaller (P < .005) than HTV based on three-way pairwise comparison between the SPR,
WMP, and HTV measurements are marked with asterisk.
Figure 1. Illustrative example of discordant localization of the suspected prostate cancer (PCa), where whole mount pathology (WMP) was
necessary to accurately identify the PCa. Top: PCa localization using whole mount annotations as the reference; the PCa chosen was identified
on the left of the patient’s prostate, as defined fromWMP. Bottom: PCa localization using SPR, however, chose a suspicious-appearing lesion
on the right as the PCa (outlined in green). Note: normal peripheral zone is outlined in yellow on the same slide in this case. ADC, apparent diffu-
sion coefficient; SPR, surgical pathology report; T2W, T2-weighted imaging; WMP, whole mount pathology.
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rameters and histology, and allows for evaluation of the accu-
racy of imaging in estimating tumor volume. This study does
not address the pathology of MRI biomarkers in PCa. How-
ever, considering the existing evidence that there is a correla-
tion between mpMRI and underlying PCa pathophysiology
(eg, the inverse relationship between cellular density and
ADC (24–26), and a relationship between DCE MRI
parameters and expression of vascular endothelial growth
factor and microvascular density (27)), we believe there is a
need for direct correlation of PCa histopathology with pros-
tate MRI. This article investigated whether detailed WMP
correlation of the prostatectomy specimen is necessary for
direct correlation with mpMRI, of whether correlation
with a standard pathology report postprostatectomy is
sufficient.552We found that the use of the SPR approach led to incorrect
lesion localization in a three of 16 cases (19%). It is not clear
why there were difficulties in SPR-based pathology correlation
in these three cases. The Gleason score was 4 + 3 in one case,
and 3 + 4 in the two other cases. The volume of the lesion,
based on WMP technique, was >0.5 cc in all three cases. No
image quality problems were observed. It is possible that these
three cases illustrate false-positive findings in mpMRI. We also
cannot exclude an inconsistency in SPR reporting of the lesion
laterality. For the lesions identified correctly, the choice of the
pathology correlation approach did not result in significant dif-
ferences in tumor volumes outlined on mpMRI maps. There
was a trend toward underestimation of tumor with either path-
ologic approach compared to actual HTV. We also observed a
nonsignificant tendency of MRTVSPR volume to be less than
MRTVWMP volume, and significant volumetric (for DWI
Figure 2. Bland–Altman plots illus-
trating the relationship between histology
index tumor volume (HTV) in comparison
to the volumes estimated on magnetic
resonance (MR) imaging after correlation
with whole mount pathology (WMP; left
column) and surgical pathology report
(SPR; right column), for the individual
MR parameters. The blue horizontal line
corresponds to the mean difference,
dashed red lines show 1.96 standard de-
viation (SD) interval. In all cases, there
was a tendency for the imaging-based
approaches to underestimate HTV.
ADC, apparent diffusion coefficient;
DCE, dynamic contrast enhanced;
MRTV, magnetic resonance tumor vol-
umes; T2W, T2-weighted imaging.
TABLE 2. Mean Quantitative Parameters Extracted From the Tumor and Normal ROI Delineated Using WMP and SPR Approaches
mpMRI Parameter SPR, Tumor SPR, Normal WMP, Tumor WMP, Normal
Ktrans, min1 0.4 (0.17) 0.19 (0.1) 0.37 (0.13) 0.18 (0.09)
ve 0.26 (0.07) 0.2 (0.1) 0.26 (0.08) 0.2 (0.05)
ADC b500,  106 mm2/s 978 (200) 1714 (237) 1018 (181) 1542 (160)
ADC, apparent diffusion coefficient; mpMRI, multiparametric magnetic resonance imaging; ROI, region of interest; SPR, surgical pathology
report; WMP, whole mount pathology.
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approach and HTV. Likewise, the mean values of the quantita-
tive indices (ADC or DCE PK maps) within the outlined tu-
mor volume did not differ. The agreement of quantitative
MRI parameters within tumor ROIs localized using the two
approaches was somewhat expected, as the volumetric overlap
was quite significant, leading to consistent mean values
extracted from the ROI.
We found that bothWMP and SPR approaches result in tu-
mor volume estimates that are lower than those estimated
from histopathology. Correlation of WM HTV with
MRTV has been investigated in a number of prior studies.
Turkbey et al. (9) investigated the agreement of histopatholo-
gy- and MRI-based index tumor volume estimated inconjunction with T2W, DCE, DW, and MR spectroscopic
imaging. Their study reported high correlation between
HTV and MRTV, with the MRTV overestimating HTV by
7%. Mazaheri et al. (10) observed that MRI can either under-
estimate or overestimate HTV, depending on the specific MR
parameters used and the lesion characteristics, with T2W
MRI performing particularly poor in estimating HTV.
Several more recent studies concluded that MRI underesti-
mates PCa tumor volume (28,29), consistent with our
findings. Cornud et al. (30) report that DWI underestimated
HTV in almost half of the cases. The differences in the con-
clusions of the published studies could be explained by the
variability of tumor size and heterogeneity, which could affect
the accuracy of tumor volume estimation.553
TABLE 3. Summary of the Advantages and Disadvantages between the WMP and SPR-based Pathology to Imaging Correlation
Methods
Imaging to Pathology
Correlation Approach Advantages Disadvantages
Whole mount processing
(WMP)
 Allows for improved precision and accuracy
in imaging to pathology correlation
 Mapping of nonfocal lesions may be possible
 Pixel-level correlation and analysis may
be possible
 Enables volumetric assessment of lesion
volume in histopathology
 Modifications to the routine clinical workflow may
be required (tissue processing protocols, ex vivo
imaging, patient-specific mold processing)
 Increased processing complexity and time (in our
case, final pathology report could be delayed by
up to 2 weeks when WMP processing was applied),
without demonstrated immediate clinical benefit to
the patient
 Deformable registration is required to enable
detailed mapping to imaging; no robust, cross-site
validated, and widely available tools for such
registration exist
 Validation of registration between WMP and imag-
ing is challenging
Surgical pathology report
(SPR)
 Ubiquitously available, provided by routine
clinical workflows
 May be sufficient for focal lesion localization
in most cases
 Cannot be used reliably for mapping all lesions in
the gland
 Reporting errors (eg, due to incorrect recording of
the lesion location) are challenging to identify or
correct retrospectively
 Volumetric assessment of the lesion from histopa-
thology is not possible
SPR, surgical pathology report; WMP, whole mount pathology.
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duced minimum changes to the standard clinical routine for
correlation with mpMRI to identify the location of the index
lesion. Image registration techniques that enable detailed
mapping between imaging and digitized pathology slides
have been proposed (31,32). However, such techniques
often require significant alterations to the clinical processing
routine that can make their implementation challenging in
practice. Even the most basic deviations from the standard
of care processing, such as the use of WM sectioning instead
of quartered slides or more, introduce delays while not
providing any additional information necessary for clinical
care (33). More complex approaches can introduce multiple
modifications to routine clinical pathology specimen pro-
cessing (eg, ex vivo MRI of the specimen, embedding of
the traceable strands into the specimen) and in extreme in-
stances can create the possibility for making error or
compromising the quality of the analysis, which could be
detrimental to patient management. As a result, it is desired
to use the simplest possible approach for correlating imaging
to pathology, which motivated our comparison of the two
approaches that are the most straightforward to implement.
Clearly, both WMP- and SPR-based approaches have
advantages and disadvantages, which we summarized in
Table 3. We suggest that the choice of the specific technique
used for correlation of pathology to imaging should be
determined on a case by case basis based on the technical
capabilities and resources available in a given situation, as
well as the specific needs of the study.554Our study has several limitations. The number of lesions
used in our analysis is small. This is due to the fact that we
limited our study to a well-defined group of significant-
volume PZ tumors ($0.5 cc) without hemorrhagic artifacts.
We did not consider smaller lesions as it has been suggested
by several studies that the focal lesion is the biological driver
of PCa in the individual patient (9,22,34,35). We did not
score reader confidence level for tumors identified in MRI,
so we cannot assess whether the accuracy of lesion
localization is actually dependent on the confidence level.
Our study focused on PCa patients who underwent
prostatectomy and did not consider the use of biopsy data
for correlation of the index lesion with the imaging. Sextant
core needle biopsy of the prostate gland under the guidance
of the transrectal ultrasound is commonly performed. It is
possible for such samples to be marked as to their location
within the gland, thus facilitating spatial correlation with
the imaging based on the prostate zonal anatomy (36). How-
ever, consistency of the tissue core labeling differs across the
institutions, and sampling error can be quite large: up to
46% of patients can have false-negative results on repeat
sextant biopsy (37–39).
In conclusion, WMP is necessary to accurately localize all
PCa index lesions. For the purposes of tumor volume mea-
surement and quantitative mpMRI assessment of the majority
of index lesions, which can be accurately localized through
correlation with SPR, there is no significant difference in
tumor volumes contoured or quantitative metrics obtained
from the TROIs, although overall tumor volumes obtained
Academic Radiology, Vol 22, No 5, May 2015 PATHOLOGY CORRELATION IN PCA MPMRI ANALYSISwith MR were smaller than those estimated from WM
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